Activating mutations in STAT3 and STAT5 differentially affect cellular proliferation and apoptotic resistance in Multiple Myeloma cells

Cancer Biology and Therapy

Volumn 3, Issue 2, 2004, Pages 188-194

  Hodge, David R ^a   Xiao, Weihua ^b   Li, Hua Wang ^b   Li, Dapei ^a   Farrar, William L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

Activated STAT factors; Cytokine mediated resistance to apoptosis; IGF 1; IL 6; Multiple myeloma

Indexed keywords

CYTOKINE; DEXAMETHASONE; FAS LIGAND; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; SOMATOMEDIN C; STAT PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; STAT5A PROTEIN; ANTIINFLAMMATORY AGENT; DNA BINDING PROTEIN; ENZYME INHIBITOR; FASLG PROTEIN, HUMAN; MEMBRANE PROTEIN; MILK PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; STAT3 PROTEIN, HUMAN; STAT5A PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN;

APOPTOSIS; ARTICLE; BLOOD LEVEL; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DOWNSTREAM PROCESSING; EXPOSURE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MUTATION; MYELOMA CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; CELL CULTURE; CELL DIVISION; DRUG ANTAGONISM; DRUG EFFECT; GEL MOBILITY SHIFT ASSAY; GENETICS; METABOLISM; PATHOLOGY; RETROVIRUS;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; CELL DIVISION; DEXAMETHASONE; DNA-BINDING PROTEINS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME INHIBITORS; FAS LIGAND PROTEIN; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INTERLEUKIN-6; MAP KINASE SIGNALING SYSTEM; MEMBRANE GLYCOPROTEINS; MILK PROTEINS; MULTIPLE MYELOMA; MUTATION; RETROVIRIDAE; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED;

EID: 5444274132     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.3.2.621     Document Type: Article

References (42)

1. Biggs DD, Kraj P, Goldman J, Jefferies L, Carchidi C, Anderson K, et al. Immunoglobulin gene sequence analysis to further assess B-cell origin of multiple myeloma. Clin Diagn Lab Immunol 1995; 2:44-52.
2. Anderson KC, Cochran M, Barut BA. Phenotypic and functional characterization of normal and malignant terminal B (plasma) cells. Eur J Haematol Suppl 1989; 51:19-26.
3. Ogata A, Chauhan D, Urashima M, Teoh G, Treon SP, Anderson KC. Blockade of mitogen-activated protein kinase cascade signaling in interleukin 6-independent multiple myeloma cells. Clin Cancer Res 1997; 3:1017-22.
4. Cheung WC, Van Ness B. Distinct IL-6 signal transduction leads to growth arrest and death in B cells or growth promotion and cell survival in myeloma cells. Leukemia 2002; 16:1182-8.
5. Tai YT, Podar K, Mitsiades N, Lin B, Mitsiades C, Gupta D, et al. CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-κB signaling. Blood 2002; 101:2762-9.
6. Rowley M, Van Ness B. Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: Implications for disease progression and therapeutic response. Oncogene 2002; 21:8769-75.
7. Frassanito MA, Cusmai A, Iodice G, Dammacco F. Autocrine interleukin-6 production and highly malignant multiple myeloma: Relation with resistance to drug-induced apoptosis. Blood 2001; 97:483-9.
8. Chauhan D, Uchiyama H, Urashima M, Yamamoto K, Anderson KC. Regulation of interleukin 6 in multiple myeloma and bone marrow stromal cells. Stem Cells 1995; 13(Suppl 2):35-9.
9. Hata H, Matsuzaki H, Takeya M, Yoshida M, Sonoki T, Nagasaki A, et al. Expression of Fas/Apo-1 (CD95) and apoptosis in tumor cells from patients with plasma cell disorders. Blood 1995; 86:1939-45.
10. Ivanov VN, Krasilnikov M, Ronai Z. Regulation of Fas expression by STAT3 and c-Jun is mediated by phosphatidylinositol 3-kinase-AKT signaling. J Biol Chem 2002; 277:4932-44.
11. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10:105-15.
12. Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, et al. Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: Therapeutic implications. Oncogene 2002; 21:5673-83.
13. Ge NL, Rudikoff S. Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood 2000; 96:2856-61.
14. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000; 19:2474-88.
15. Gouilleux-Gruart V, DebierreGrockiego F, Gouilleux F, Capiod JC, Claisse JF, Delobel J, et al. Activated Stat related transcription factors in acute leukemia. Leuk. Lymphoma 1997; 28:83-8.
16. Gouilleux-Gruart V, Gouilleux F, Desaint C, Claisse JF, Capiod JC, Delobel J, et al. STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood 1996; 87:1692-7.
17. Yang, J, Kennelly JJ, Baracos VE. The activity of transcription factor Stat5 responds to prolactin, growth hormone, and IGF-I in rat and bovine mammary explant culture. J Anim Sci 2000; 78:3114-25.
18. Waxman DJ, Ram PA, Park SH, Choi HK. Intermittent plasma growth hormone triggers tyrosine phosphorylation and nuclear translocation of a liver-expressed, Stat 5-related DNA binding protein. Proposed role as an intracellular regulator of male-specific liver gene transcription. J Biol Chem 1995; 270:13262-70.
19. Storz P, Doppler H, Pfizenmaier K, Muller G. Insulin selectively activates STAT5b, but not STAT5a, via a JAK2-independent signalling pathway in Kym-1 rhabdomyosarcoma cells. FEBS Lett 1999; 464:159-63.
20. Ram PA, Park SH, Choi HK, Waxman DJ. Growth hormone activation of Stat 1, Stat 3, and Stat 5 in rat liver. Differential kinetics of hormone desensitization and growth hormone stimulation of both tyrosine phosphorylation and serine/threonine phosphorylation. J Biol Chem 1996; 271:5929-40.
21. Cken J, Sadowski HB, Kohanski RA, Wang LH. Stat5 is a physiological substrate of the insulin receptor. Proc Natl Acad Sci USA 1997; 94:2295-300.
22. Zong CS, Chan J, Levy DE, Horvath C, Sadowski HB, Wang LH. Mechanism of STAT3 activation by insulin-like growth factor I receptor. J Biol Chem 2000; 275:5099-105.
23. Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary Dexamethasone treatment of multiple myeloma. Blood 1992; 80:887-90.
24. Chauhan D, Pandey P, Ogata A, Teoh G, Treon S, Urashima M, et al. Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism. Oncogene 1997; 15:837-43.
25. Chauhan D, Hideshima T, Pandey P, Treon S, Teoh G, Raje N, et al. RAFTK/ PYK2-dependent and -independent apoptosis in multiple myeloma cells. Oncogene 1999; 18, 6733-40.
26. Xu F, Gardner A, Tu Y, Michl P, Prager D, Lichtenstein A. Multiple myeloma cells are protected against Dexamethasone-induced apoptosis by insulin-like growth factors. Br J Haematol 1997; 97:429-40.
27. Akiyama M, Hideshima T, Hayashi T, Tai YT, Mitsiades CS, Mitsiades N, et al. Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res 2002; 62:3876-82.
28. Chauhan D, Kharbanda S, Ogata A, Urashima M, Teoh G, Robertson M, et al. Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood 1997; 89:227-34.
29. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, et al. Stat3 as an oncogene. Cell 1999; 98:295-303.
30. Onishi M, Nosaka T, Misawa K, Mui AL, Gorman D, McMahon M, et al. Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation. Mol Cell Biol 1998; 18:3871-9.
31. Spiekermann K, Pau M, Schwab R, Schmieja K, Franzrahe S, Hiddemann W. Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells. Exp Hematol 2002; 30:262-71.
32. Hayakawa F, Towatari M, Iida H, Wakao H, Kiyoi H, Naoe T, et al. Differential constitutive activation between STAT-related proteins and MAP kinase in primary acute myelogenous leukaemia. Br J Haematol 1998; 101:521-8.
33. Chai SK, Nickols GL, Rothman P. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol 1997; 159:4720-8.
34. Kinsella TM, Nolan GP. Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Hum Gene Ther 1996; 7:1405-13.
35. Hooijberg E, Ruizendaal JJ, Snijders PJ, Kueter EW, Walboomers JM, Spits H. Immortalization of human CD8+ T cell clones by ectopic expression of telomerase reverse transcriptase. J Immunol 2000; 165:4239-45.
36. Westendorf JJ, Ahmann GJ, Greipp PR, Witzig TE, Lust JA, Jelinek DF. Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6. Leukemia 1996; 10, 866-76.
37. Chauhan D, Pandey P, Hideshima T, Treon S, Raje N, Davies FE, et al. SHP2 mediates the protective effect of interleukin-6 against Dexamethasone-induced apoptosis in multiple myeloma cells. J Biol Chem 2000; 275:27845-50.
38. Wu CJ, O'Rourke DM, Feng GS, Johnson GR, Wang Q, Greene MI. The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors. Oncogene 2001; 20:6018-25.
39. Jourdan M, De Vos J, Mechti N, Klein B. Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-α and insulin-like growth factor 1. Cell Death Differ 2000; 7:1244-52.
40. Jee SH, Chiu HC, Tsai TF, Tsai WL, Liao YH, Chu CY, et al. The phosphotidyl inositol 3-kinase/Akt signal pathway is involved in interleukin-6-mediated Mcl-1 upregulation and anti-apoptosis activity in basal cell carcinoma cells. J Invest Dermatol. 2002; 119:1121-7.
41. Huang M, Dorsey JF, Epling-Burnette PK, Nimmanapalli R, Landowski TH, Mora LB, et al. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene 2002; 21:8804-16.
42. Spets H, Stromberg T, Georgii-Hemming P, Siljason J, Nilsson K, Jernberg-Wiklund H. Expression of the bcl-2 family of pro- and anti-apoptotic genes in multiple myeloma and normal plasma cells: regulation during interleukin-6(IL-6)-induced growth and survival. Eur J Haematol 2002; 69:76-89.